Abstract
Background Mass drug administration (MDA) of ivermectin for onchocerciasis has been disrupted by the SARS-CoV-2 (COVID-19) pandemic. Mathematical modelling can help predict how missed/delayed MDA will affect short-term epidemiological trends and elimination prospects by 2030.
Methods Two onchocerciasis transmission models (EPIONCHO-IBM and ONCHOSIM) are used to simulate microfilarial prevalence trends, elimination probabilities, and age-profiles of Onchocerca volvulus microfilarial prevalence and intensity, for different treatment histories and transmission settings, assuming no interruption, a 1-year (2020) or 2-year (2020–2021) interruption. Biannual MDA or increased coverage upon MDA resumption are investigated as remedial strategies.
Results Programmes with shorter MDA histories and settings with high pre-intervention endemicity will be the most affected. Biannual MDA is more effective than increasing coverage for mitigating COVID-19’s impact on MDA. Programmes which had already switched to biannual MDA should be minimally affected. In high transmission settings with short treatment history, a 2-year interruption could lead to increased microfilarial load in children (EPIONCHO-IBM) or adults (ONCHOSIM).
Conclusions Programmes with shorter (annual MDA) treatment histories should be prioritised for remedial biannual MDA. Increases in microfilarial load could have short- and long-term morbidity and mortality repercussions. These results can guide decision-making to mitigate the impact of COVID-19 on onchocerciasis elimination.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Bill and Melinda Gates Foundation via the NTD Modelling Consortium (grant number OPP1184344); the UK Medical Research Council (MRC Doctoral Training Programme award to PM); MRC and the UK Department for International Development (DFID) Joint Centre Funding under the MRC/DFID Concordat agreement of the European Union and European and Developing Countries Clinical Trials Partnership 2 (grant number MR/R015600/1 (JIDH, PM, MGB).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Not applicable. This is a modelling study and no data are used.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Data availability statement: No new data were used in this study. The model code is available on Github.
Data Availability
Data availability statement: No new data were used in this study. The model code is available on Github.
Abbreviations
- ABR
- annual biting rate
- APOC
- African Programme for Onchocerciasis Control
- EOT
- elimination of transmission
- IBM
- individual-based model
- MDA
- mass drug administration
- aMDA
- annual mass drug administration
- bMDA
- biannual mass drug administration
- MDP
- Mectizan Donation Program
- NTD
- neglected tropical disease
- OCP
- Onchocerciasis Control Programme in West Africa
- PCT
- preventive chemotherapy and transmission control
- USAID
- United States Agency for International Development
- WHO
- World Health Organization.